Drugs / Olesoxime

Trials 9 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT02835976 Jul → Sep 2014 Hoffmann-La Roche Completed No outcome recorded
Phase 1 NCT01808885 Apr 2013 → Jan 2014 relapsing-remitting multiple sclerosis Hoffmann-La Roche Completed No outcome recorded
Phase 25 trials
Phase 2 NCT02628743 Jan 2016 → Dec 2018 spinal muscular atrophy Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT01302600 Nov 2010 → Oct 2013 spinal muscular atrophy, type II, spinal muscular atrophy, type III Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT00876538 Mar 2009 → Sep 2010 chemotherapy-induced neuropathy Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT00666016 Apr 2008 → Feb 2009 metabolic dysfunction-associated steatohepatitis Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT00496457 May 2007 → Dec 2008 diabetic polyneuropathy Hoffmann-La Roche Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT01285583 Oct 2010 → Mar 2012 amyotrophic lateral sclerosis Hoffmann-La Roche Completed No outcome recorded
Phase 31 trial
Phase 3 NCT00868166 Apr 2009 → Sep 2011 amyotrophic lateral sclerosis Hoffmann-La Roche Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as olesoxime “Each patient will be treated with olesoxime (TRO19622) until the results of the double-blind trial become available with a maximum of 15 months.” NCT01285583
6

NCT02628743

NCT01808885

NCT00868166

NCT00876538

NCT01302600

NCT02835976

Known as 4-cholest-en-3-one, oxime ChEMBL registry synonym — accepted as the source's own label CHEMBL3545254
Known as Cholest-4-en-3-one, oxime ChEMBL registry synonym — accepted as the source's own label CHEMBL3545254
Known as NSC-21311 ChEMBL registry synonym — accepted as the source's own label CHEMBL3545254
Known as Olesoxima ChEMBL registry synonym — accepted as the source's own label CHEMBL3545254
Known as TRO19622 “Phase II, Multicenter, Randomized, Adaptive, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Year Old Spinal Muscular...” NCT01302600
5

“Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks” NCT00496457

“olesoxime (TRO19622)” NCT01808885

“Olesoxime (TRO19622)” NCT00876538

NCT00666016

NCT01285583

Known as TRO19622 (olesoxime) TRO19622 (olesoxime)NCT01808885
Modality Small molecule CHEMBL3545254
Route Oral “TRO19622 administered PO daily for 6 weeks” NCT00496457